{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T12:05:45Z","timestamp":1773921945563,"version":"3.50.1"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2019,7,27]],"date-time":"2019-07-27T00:00:00Z","timestamp":1564185600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>Despite the increasing use of early invasive strategies in non-ST-elevation acute coronary syndromes (NSTE-ACS), optimal initial antithrombotic therapy (ATT) based on the safety\/efficacy profile of all guideline-recommended combinations remains crucial for the early management of both medically and invasively treated NSTE-ACS patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>Randomized controlled trials on ATT in NSTE-ACS\/unstable angina reporting early (within 14\u2009days) major adverse cardiovascular events (MACE) and major bleeding were selected. Overall, 3799 studies were screened, 117 clinical trials were assessed as potentially eligible, 20 trials were included in the study. According to treatment and type of intervention, nine different meta-analyses were performed including a total of 88\u00a0748 patients. A significant reduction of trial-defined MACE was found for aspirin vs. placebo [odds ratio (OR), 0.57; 95% confidence interval (CI), 0.34\u20130.96], heparin vs. placebo (OR, 0.38; 95% CI, 0.15\u20130.97), aspirin\u2009+\u2009heparin vs. placebo (OR, 0.32; 95% CI, 0.18\u20130.59), aspirin\u2009+\u2009heparin vs. aspirin (OR, 0.57; 95% CI, 0.42\u20130.79), aspirin\u2009+\u2009low molecular weight heparin (LMWH) vs. aspirin\u2009+\u2009unfractionated heparin (UFH; OR, 0.81; 95% CI, 0.69\u20130.95) and aspirin\u2009+\u2009ticagrelor\/prasugrel\u2009+\u2009heparins vs. aspirin\u2009+\u2009clopidogrel\u2009+\u2009heparins (OR, 0.76; 95% CI, 0.62\u20130.94). A significant decrease in major bleeding was found only for fondaparinux vs. LMWH on the background of aspirin\u2009+\u2009clopidogrel (OR, 0.52; 95% CI, 0.44\u20130.62) despite a clear trend towards increased bleeding for heparin compared to aspirin, aspirin\u2009+\u2009heparin compared to placebo, aspirin\u2009+\u2009heparin compared to aspirin, aspirin\u2009+\u2009P2Y12inhibitors\u2009+\u2009UFH\/LMWH compared to aspirin\u2009+\u2009UFH\/LMWH, and aspirin\u2009+\u2009ticagrelor\/prasugrel\u2009+\u2009heparins compared to aspirin\u2009+\u2009clopidogrel\u2009+\u2009heparins.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>To our knowledge, these findings are the first to report the safety and efficacy of all the various combinations of currently recommended ATT for the early management of NSTE-ACS, providing a comprehensive evidence-base to guide decisions depending on the patients\u2019 bleeding risk and treatment strategy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ehjcvp\/pvz031","type":"journal-article","created":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T07:25:57Z","timestamp":1563953157000},"page":"43-56","source":"Crossref","is-referenced-by-count":34,"title":["Antithrombotic therapy in the early phase of non-ST-elevation acute coronary syndromes: a systematic review and meta-analysis"],"prefix":"10.1093","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3909-182X","authenticated-orcid":false,"given":"Mattia","family":"Galli","sequence":"first","affiliation":[{"name":"Department of Cardiovascular and Thoracic Sciences, Fondazione Policlinico A. Gemelli IRCCS, Largo Francesco Vito, 1, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1456-6430","authenticated-orcid":false,"given":"Felicita","family":"Andreotti","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular and Thoracic Sciences, Fondazione Policlinico A. Gemelli IRCCS, Largo Francesco Vito, 1, Rome, Italy"},{"name":"Universit\u00e0 Cattolica del Sacro Cuore, Largo Francesco Vito, 1, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenico","family":"D\u2019Amario","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular and Thoracic Sciences, Fondazione Policlinico A. Gemelli IRCCS, Largo Francesco Vito, 1, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rocco","family":"Vergallo","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular and Thoracic Sciences, Fondazione Policlinico A. Gemelli IRCCS, Largo Francesco Vito, 1, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni Maria","family":"Vescovo","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Cardiac, Thoracic and Vascular Sciences, University of Padova, Via 8 Febbraio 1848, 2, Padova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Giraldi","sequence":"additional","affiliation":[{"name":"Section of Hygiene, Institute of Public Health, Universit\u00e0 Cattolica del Sacro Cuore, Largo Agostino Gemelli, 8, Roma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Migliaro","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular and Thoracic Sciences, Fondazione Policlinico A. Gemelli IRCCS, Largo Francesco Vito, 1, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pietro","family":"Ameri","sequence":"additional","affiliation":[{"name":"Italian IRCCS Cardiovascular Network, IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi, 10, Genova, Italy"},{"name":"Dipartimento di Medicina Interna e Specialit\u00e0 Mediche (DIMI), Universit\u00e0 di Genova, Largo R. Benzi 15, Genova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Italo","family":"Porto","sequence":"additional","affiliation":[{"name":"Italian IRCCS Cardiovascular Network, IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi, 10, Genova, Italy"},{"name":"Dipartimento di Medicina Interna e Specialit\u00e0 Mediche (DIMI), Universit\u00e0 di Genova, Largo R. Benzi 15, Genova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9404-8846","authenticated-orcid":false,"given":"Filippo","family":"Crea","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular and Thoracic Sciences, Fondazione Policlinico A. Gemelli IRCCS, Largo Francesco Vito, 1, Rome, Italy"},{"name":"Universit\u00e0 Cattolica del Sacro Cuore, Largo Francesco Vito, 1, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,7,27]]},"reference":[{"key":"2020010703580082200_pvz031-B1","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1093\/eurheartj\/ehu043","article-title":"German nationwide data on current trends and management of acute myocardial infarction: discrepancies between trials and real-life","volume":"35","author":"Freisinger","year":"2014","journal-title":"Eur Heart J"},{"key":"2020010703580082200_pvz031-B2","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1093\/ehjcvp\/pvw005","article-title":"P2Y12 receptor inhibitors in patients with non-ST-elevation acute coronary syndrome in the real world: use, patient selection, and outcomes from contemporary European registries","volume":"2","author":"Zeymer","year":"2016","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2020010703580082200_pvz031-B3","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1056\/NEJMra1216063","article-title":"Mechanisms of acute coronary syndromes and their implications for therapy","volume":"368","author":"Libby","year":"2013","journal-title":"N Engl J Med"},{"key":"2020010703580082200_pvz031-B4","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1161\/01.CIR.86.5.1407","article-title":"Randomized trial of thrombolysis versus heparin in unstable angina","volume":"86","author":"Schreiber","year":"1992","journal-title":"Circulation"},{"key":"2020010703580082200_pvz031-B5","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1161\/01.CIR.89.4.1545","article-title":"Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB Trial. Thrombolysis in Myocardial Ischemia","volume":"89","year":"1994","journal-title":"Circulation"},{"key":"2020010703580082200_pvz031-B6","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","article-title":"2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"37","author":"Roffi","year":"2016","journal-title":"Eur Heart J"},{"key":"2020010703580082200_pvz031-B7","doi-asserted-by":"crossref","first-page":"261","DOI":"10.7326\/0003-4819-158-4-201302190-00006","article-title":"Optimal timing of coronary invasive strategy in non-ST-segment elevation acute coronary syndromes: a systematic review and meta-analysis","volume":"158","author":"Navarese","year":"2013","journal-title":"Ann Intern Med"},{"key":"2020010703580082200_pvz031-B8","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1016\/S0140-6736(00)02324-2","article-title":"Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis","volume":"355","author":"Eikelboom","year":"2000","journal-title":"Lancet"},{"key":"2020010703580082200_pvz031-B9","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1056\/NEJM198810273191701","article-title":"Aspirin, heparin, or both to treat acute unstable angina","volume":"319","author":"Th\u00e9roux","year":"1988","journal-title":"N Engl J Med"},{"key":"2020010703580082200_pvz031-B10","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1161\/01.CIR.89.1.81","article-title":"Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial. Antithrombotic Therapy in Acute Coronary Syndromes Research Group","volume":"89","author":"Cohen","year":"1994","journal-title":"Circulation"},{"key":"2020010703580082200_pvz031-B11","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0735-1097(94)90539-8","article-title":"Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina","volume":"24","author":"Holdright","year":"1994","journal-title":"J Am Coll Cardiol"},{"key":"2020010703580082200_pvz031-B12","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0140-6736(96)91270-2","article-title":"Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group","volume":"347","year":"1996","journal-title":"Lancet"},{"key":"2020010703580082200_pvz031-B13","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJM199708143370702","article-title":"A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and safety of subcutaneous enoxaparin in non-Q-wave coronary events study group","volume":"337","author":"Cohen","year":"1997","journal-title":"N Engl J Med"},{"key":"2020010703580082200_pvz031-B14","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1161\/01.CIR.100.15.1602","article-title":"Assessment of the treatment effect of enoxaparin for unstable angina\/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis","volume":"100","author":"Antman","year":"1999","journal-title":"Circulation"},{"key":"2020010703580082200_pvz031-B15","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N Engl J Med"},{"key":"2020010703580082200_pvz031-B16","first-page":"45","article-title":"Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial","volume":"292","author":"Ferguson","year":"2004","journal-title":"JAMA"},{"key":"2020010703580082200_pvz031-B17","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1016\/j.jacc.2004.02.051","article-title":"A dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes: the Pentasaccharide in Unstable Angina (PENTUA) Study","volume":"43","author":"Simoons","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"2020010703580082200_pvz031-B18","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.jacc.2009.03.062","article-title":"Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes treated with glycoprotein IIb\/IIIa inhibitors or thienopyridines: results from the OASIS 5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) trial","volume":"54","author":"Jolly","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2020010703580082200_pvz031-B19","first-page":"879","article-title":"Comparison of safety and efficacy between fondaparinux and nadroparin in non-ST elevation acute coronary syndromes","volume":"124","author":"Yan","year":"2011","journal-title":"Chin Med J"},{"key":"2020010703580082200_pvz031-B20","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1093\/ehjcvp\/pvv006","article-title":"Contemporary antithrombotic strategies in patients with acute coronary syndromes managed without revascularization: insights from the EYESHOT study","volume":"1","author":"De Luca","year":"2015","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2020010703580082200_pvz031-B21","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1001\/jama.290.12.1593","article-title":"Evaluation of prolonged antithrombotic pretreatment (\u201ccooling-off\u201d strategy) before intervention in patients with unstable coronary syndromes: a randomized controlled trial","volume":"290","author":"Neumann","year":"2003","journal-title":"JAMA"},{"key":"2020010703580082200_pvz031-B22","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur Heart J"},{"key":"2020010703580082200_pvz031-B23","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/eurheartj\/ehy394","article-title":"2018 ESC\/EACTS guidelines on myocardial revascularization","volume":"40","author":"Neumann","year":"2019","journal-title":"Eur Heart J"},{"key":"2020010703580082200_pvz031-B24","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ijcard.2018.10.087","article-title":"Early anticoagulation in the current management of NSTE-ACS: evidence, guidelines, practice and perspectives","volume":"275","author":"Galli","year":"2019","journal-title":"Int J Cardiol"},{"key":"2020010703580082200_pvz031-B25","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1001\/jama.1996.03540100055028","article-title":"Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis","volume":"276","author":"Oler","year":"1996","journal-title":"JAMA"},{"key":"2020010703580082200_pvz031-B26","first-page":"CD003462","article-title":"Heparin versus placebo for non-ST elevation acute coronary syndromes","volume":"6","author":"Andrade-Castellanos","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2020010703580082200_pvz031-B27","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1160\/TH14-12-1066","article-title":"Comparative efficacy and safety of anticoagulant strategies for acute coronary syndromes. Comprehensive network meta-analysis of 42 randomised trials involving 117,353 patients","volume":"114","author":"Navarese","year":"2015","journal-title":"Thromb Haemost"},{"key":"2020010703580082200_pvz031-B28","doi-asserted-by":"crossref","first-page":"b2700.","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"2020010703580082200_pvz031-B29","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"2020010703580082200_pvz031-B30","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/0140-6736(90)92336-G","article-title":"Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease","volume":"336","year":"1990","journal-title":"Lancet"},{"key":"2020010703580082200_pvz031-B31","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/S0140-6736(81)92399-0","article-title":"Trial of heparin versus atenolol in prevention of myocardial infarction in intermediate coronary syndrome","volume":"1","author":"Telford","year":"1981","journal-title":"Lancet"},{"key":"2020010703580082200_pvz031-B32","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1161\/01.CIR.88.5.2045","article-title":"Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina","volume":"88","author":"Theroux","year":"1993","journal-title":"Circulation"},{"key":"2020010703580082200_pvz031-B33","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1161\/01.CIR.100.15.1593","article-title":"Enoxaparin prevents death and cardiac ischemic events in unstable angina\/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial","volume":"100","author":"Antman","year":"1999","journal-title":"Circulation"},{"key":"2020010703580082200_pvz031-B34","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1053\/euhj.1999.1879","article-title":"Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome)","volume":"20","year":"1999","journal-title":"Eur Heart J"},{"key":"2020010703580082200_pvz031-B35","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1161\/01.CIR.96.1.61","article-title":"Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC)","volume":"96","author":"Klein","year":"1997","journal-title":"Circulation"},{"key":"2020010703580082200_pvz031-B36","first-page":"648","article-title":"Comparative efficacy of once daily parnaparin and unfractionated heparin in unstable angina pectoris: pRIME CARE study","volume":"57","year":"2005","journal-title":"Indian Heart J"},{"key":"2020010703580082200_pvz031-B37","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0002-9149(00)00879-1","article-title":"Role of low-molecular-weight heparins in the management of patients with unstable angina pectoris and non-Q-wave acute myocardial infarction","volume":"85","author":"Monrad","year":"2000","journal-title":"Am J Cardiol"},{"key":"2020010703580082200_pvz031-B38","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1056\/NEJMoa1308075","article-title":"Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes","volume":"369","author":"Montalescot","year":"2013","journal-title":"N Engl J Med"},{"key":"2020010703580082200_pvz031-B39","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1161\/01.CIR.0000051362.96946.15","article-title":"Early and late effects of clopidogrel in patients with acute coronary syndromes","volume":"107","author":"Yusuf","year":"2003","journal-title":"Circulation"},{"key":"2020010703580082200_pvz031-B40","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"2020010703580082200_pvz031-B41","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/clc.22733","article-title":"Relative efficacy and safety of ticagelor vs clopidogrel as a function of time to invasive management in non-ST-segment elevation acute coronary syndrome in the PLATO trial","volume":"40","author":"Pollack","year":"2017","journal-title":"Clin Cardiol"},{"key":"2020010703580082200_pvz031-B42","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJMoa055443","article-title":"Comparison of fondaparinux and enoxaparin in acute coronary syndromes","volume":"354","author":"Yusuf","year":"2006","journal-title":"N Engl J Med"},{"key":"2020010703580082200_pvz031-B43","doi-asserted-by":"crossref","first-page":"g6269","DOI":"10.1136\/bmj.g6269","article-title":"Reappraisal of thienopyridine pretreatment in patients with non-ST elevation acute coronary syndrome: a systematic review and meta-analysis","volume":"349","author":"Bellemain-Appaix","year":"2014","journal-title":"BMJ"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvz031\/29228590\/pvz031.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ehjcvp\/article-pdf\/6\/1\/43\/31717495\/pvz031.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ehjcvp\/article-pdf\/6\/1\/43\/31717495\/pvz031.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T03:58:23Z","timestamp":1578369503000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/6\/1\/43\/5539751"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,27]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,7,27]]},"published-print":{"date-parts":[[2020,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvz031","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,1]]},"published":{"date-parts":[[2019,7,27]]}}}